Calling all runners and walkers, it’s time to lace up and train for a local 3.1-mile race.
Participants will be lining up at the Spanish River Athletic Complex on Sunday, April 27, at 7:30 a.m. for the Run from the Rays 5K. The complex is located at 1370 NW Spanish River Blvd., Boca Raton, across the Spanish River Library.
Registration is $25 through April 21 and goes up to $30 after that. Kids, ages 1-8, can run free in the Run from the Rays kids’ fun run. There will be a bounce house, music, refreshments and a pancake breakfast.
The run benefits SafeSun, Inc., a charity started by three Boca Raton families. The Nachlas, Luciano and Friedman families founded the charity to raise funds for the prevention and treatment of melanoma and other skin cancers..
Local athlete Fran Nachlas, co-founder and director of the event, says the cause was near and dear to the families for many reasons. The parents wanted to start a charity to get their kids involved and teach them about philanthropy. Her husband, Nathan Nachlas, a facial plastic and reconstructive surgeon who reconstructs patients’ faces after skin cancer removal, lost an uncle to melanoma. Their daughter, Hannah, is studying pre-med at New York University has aspirations to be a dermatologist.
Last year, more than $30,000 was raised at the run. This year, they hope to surpass that number,
In other news….
Cleveland Clinic Florida in Weston announced that it will be participating in a nationwide clinical trial that will study the effectiveness of an FDA-approved diabetes drug for preventing Alzheimer’s disease. The study also aims to determine whether a new genetic biomarker, TOMM40, is an indication that a person is at elevated risk for developing Alzheimer’s.
TOMMORROW is the largest nationwide Alzheimer’s disease prevention trial to date, enrolling about 5,800 people across the country.
To participate, applicants must be Palm Beach, Broward or Miami-Dade county residents at high-risk of or predisposed to Alzheimer's. Hospital researchers expect to screen hundreds of people in order to enroll a group of 120.
Study participants who are randomly chosen to take the active drug will take pioglitazone (AD-4833), which regulates glucose metabolism and insulin sensitivity. It also reduces inflammation and has a protective effect in the brain that can prevent high risk-patients from developing mild cognitive disorder and Alzheimer’s disease, according to a Cleveland Clinic press release.
“Florida is home to nearly 10 percent of individuals in the United States who suffer from Alzheimer’s disease, and with our large senior population here in South Florida, it is an ideal community from which to draw participants for this trial,” says Dr. Nestor Galvez, principal investigator at Cleveland Clinic Florida.
People who want to enroll for the trial must be between 65 and 83 years old and have normal thinking and reasoning skills, with no symptoms of memory loss. All who participate in TOMMORROW will undergo a genetic blood test to determine risk.
“If we do not develop the means to prevent or stop the progression of Alzheimer’s, the 5.2 million Americans with this disease could balloon to 7.1 million in just over a decade,” says Dr. Po-Heng Tsai, co-investigator of TOMMORROW at Cleveland Clinic. “The participants in the TOMMORROW study, individuals who have not yet been affected but have a real possibility of a future with Alzheimer’s disease, have an invaluable role to play in helping researchers achieve the breakthroughs that could improve the lives of so many.”
For more information about the TOMMORROW trial, call 954/659-6428 or toll free, 1-844-ALZ-TRIAL (1-844-259-8742).
For more posts from The Fit Life, click here.
Lisette Hilton, president of Words Come Alive, has had the luxury of reporting on health, fitness and other hot topics for more than 23 years. The longtime Boca Raton resident, University of Florida graduate and fitness buff writes for local, regional and national publications and websites.
Find out more on www.wordscomealive.com.